Question 1

What specific criteria do I need to meet to participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations clinical trial (NCT06391944). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination of JMT101 and Osimertinib compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations clinical trial (NCT06391944). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of these treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations clinical trial (NCT06391944). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations clinical trial (NCT06391944). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations clinical trial (NCT06391944). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations clinical trial (NCT06391944). Contact the study team or your healthcare provider for specific answers.

What this study is about